Biocryst director receives RSU and option grants

BIOCRYST PHARMACEUTICALS INC director Theresa Heggie reported equity awards received as part of non-employee director compensation.

Rhea-AI Filing Summary

BIOCRYST PHARMACEUTICALS INC director Theresa Heggie reported equity awards received as part of non-employee director compensation. She acquired 15,294 shares of Common Stock through a grant of Restricted Stock Units that will vest on the first anniversary of the grant date. She also received an automatic stock option grant covering 33,540 shares of Common Stock at an exercise price of $8.50 per share, expiring on June 11, 2036. Following these awards, she directly holds 80,646 shares of Common Stock. These awards were made under the company’s Non-Employee Director Compensation Policy and represent routine compensation, not open-market buying or selling.

Insider Trade Summary

Grant/Award: 48,834 shares

Grant/Award 2 txns

Insider HEGGIE THERESA

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Automatic Stock Option Grant	33,540	$0.00	$0.00
Grant/Award	Common Stock	15,294	$0.00	$0.00

Holdings After Transaction: Automatic Stock Option Grant — 33,540 contracts (Direct); Common Stock — 80,646 shares (Direct)

Footnotes (2)

1. F1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
2. F2. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

Key Figures

Restricted Stock Units granted: 15,294 shares Stock options granted: 33,540 options Option exercise price: $8.50 per share +3 more

6 metrics

Restricted Stock Units granted 15,294 shares Automatic non-employee director grant; vests on first anniversary of grant

Stock options granted 33,540 options Automatic stock option grant to non-employee director

Option exercise price $8.50 per share Exercise price for 33,540 stock options

Option expiration date June 11, 2036 Expiration of automatic stock option grant

Shares underlying options 33,540 shares Underlying common stock for option grant

Shares held after transaction 80,646 shares Total direct common stock holdings after awards

Key Terms

Restricted Stock Units, Non-Employee Director Compensation Policy, Automatic Stock Option Grant, stock options

4 terms

Restricted Stock Units financial

"Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Non-Employee Director Compensation Policy financial

"pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended"

Automatic Stock Option Grant financial

"Security title: Automatic Stock Option Grant with an exercise price of $8.50 per share"

stock options financial

"Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BIOCRYST (BCRX) director Theresa Heggie report on this Form 4?

Director Theresa Heggie reported receiving equity awards as compensation, not market trades. She was granted 15,294 Restricted Stock Units and an option for 33,540 shares, reflecting routine non-employee director compensation at BioCryst Pharmaceuticals.

How many BIOCRYST (BCRX) shares does Theresa Heggie hold after the awards?

After the reported awards, Theresa Heggie directly holds 80,646 shares of BioCryst common stock. This total reflects her updated ownership position following the grant of 15,294 Restricted Stock Units under the company’s non-employee director compensation policy.

What equity awards did BIOCRYST (BCRX) grant to Theresa Heggie?

She received 15,294 Restricted Stock Units and an automatic stock option grant for 33,540 shares. Both were issued under BioCryst’s Non-Employee Director Compensation Policy as routine compensation for serving on the board.

When do Theresa Heggie’s BIOCRYST (BCRX) Restricted Stock Units vest?

The 15,294 Restricted Stock Units will vest on the first anniversary of the grant date. This one-year vesting schedule is specified in the description of awards granted under the company’s Non-Employee Director Compensation Policy.

What are the key terms of Theresa Heggie’s BIOCRYST (BCRX) stock option grant?

The automatic stock option grant covers 33,540 shares of common stock at an exercise price of $8.50 per share. The options expire on June 11, 2036, and were issued pursuant to the Director Compensation Policy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 04:06 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HEGGIE THERESA

(Last) (First) (Middle)

4505 EMPEROR BOULEVARD

SUITE 200

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		15,294(1)	A	$0	80,646	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Automatic Stock Option Grant(2)	$8.5	06/11/2026		A		33,540		06/11/2027	06/11/2036	Common Stock	33,540	$0	33,540	D

Explanation of Responses:

1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

2. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

	/s/ Alane P. Barnes, by power of attorney	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)